# CHL1 Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- The *CHL1* gene encodes a type I transmembrane glycoprotein crucial for neural development, synaptic plasticity, and tumor suppression, with its protein product featuring six immunoglobulin-like domains and five fibronectin type III repeats.
- Germline deletions and duplications of *CHL1* are associated with neurodevelopmental disorders including autism spectrum disorder (ASD) and intellectual disability, while somatic alterations like promoter hypermethylation and loss of heterozygosity (LOH) contribute to various cancers, paradoxically acting as a tumor suppressor in some (e.g., neuroblastoma) and a promoter in others (e.g., glioma).
- *CHL1* plays a significant role in pancreatic β-cell function, modulating insulin secretion and linking it to type 2 diabetes pathophysiology, with its expression regulated by complex epigenetic mechanisms including DNA methylation and microRNAs.
- Pathogenic alterations in *CHL1* are primarily copy number variations (CNVs) detected by chromosomal microarray analysis (CMA), leading to phenotypes such as intellectual disability and seizures, while SNPs and missense variants have been investigated for associations with schizophrenia and lung cancer susceptibility.
- Therapeutic strategies for *CHL1* involve restoring its expression via DNA methyltransferase inhibitors (DNMTi) and microRNA antagonists in tumor suppressor contexts, or inhibiting its function through monoclonal antibodies and small-molecule inhibitors in oncogenic contexts, with *CHL1* expression also serving as a potential pharmacogenomic biomarker for antidepressant response.
---
## Executive Summary & Key Metadata
The *CHL1* gene (Close Homolog of L1; also known as *CALL*) encodes a type I transmembrane glycoprotein belonging to the L1 subfamily of the immunoglobulin superfamily of cell adhesion molecules (IgCAMs). Initially identified through its homology to the yeast chromosome transmission fidelity gene *CTF1/CHL1* [1], the human *CHL1* gene has since been established as a critical regulator of neural development, synaptic plasticity, tumor suppression, and pancreatic β-cell function. The protein product is characterized by an extracellular region containing six immunoglobulin (Ig)-like domains and five fibronectin type III (FNIII) repeats, a single transmembrane domain, and a highly conserved cytoplasmic tail that interacts with multiple intracellular signaling scaffolds [2][3][4].
The clinical significance of *CHL1* is broad and context-dependent. Germline deletions, duplications, and point mutations are associated with a spectrum of neurodevelopmental phenotypes including autism spectrum disorder (ASD), intellectual disability, schizophrenia susceptibility, and epilepsy [3][5][6][7][8][1]. In oncology, *CHL1* functions as a tumor suppressor in neuroblastoma, nasopharyngeal carcinoma, breast cancer, and esophageal squamous cell carcinoma, yet paradoxically acts as a malignancy promoter in glioma [2][3][4][4][5]. Additionally, *CHL1* expression in pancreatic β-cells modulates insulin secretion, linking the gene to type 2 diabetes pathophysiology [6][7][8]. The gene is also subject to complex epigenetic regulation, including promoter hypermethylation in breast cancer and regulation by multiple microRNAs [1][2][3][4][5].
| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | CHL1 |
| UniProt Accession | O00533 |
| Representative PDB ID | true (see Section 2) |
| Chromosomal Locus | 3p26.3 |
| Primary Molecular Function | Cell adhesion molecule; neural development; tumor suppression; insulin secretion regulation |
| Disease & Pathology Associations | Autism spectrum disorder, intellectual disability, schizophrenia, epilepsy, neuroblastoma, breast cancer, nasopharyngeal carcinoma, glioma, type 2 diabetes, endometriosis |
---
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Genomic Coordinates
The *CHL1* gene is located on the short arm of chromosome 3 at cytogenetic band 3p26.3, a region frequently subject to copy number variations (CNVs) and loss of heterozygosity (LOH) in multiple cancer types [2][4][4]. The gene spans approximately 380 kilobases of genomic DNA on the minus strand (GRCh38/hg38: chr3:238,238,714–238,618,584). This locus is gene-dense and contains several regulatory elements that are shared with neighboring genes, including *CNTN6* and *CNTN4*, which are also implicated in neurodevelopmental disorders [6].
The 3p26.3 region is notable for its high density of low-copy repeats (LCRs) and segmental duplications, which predispose the locus to non-allelic homologous recombination (NAHR) events. Such recombination events give rise to recurrent microdeletions and microduplications involving *CHL1* alone or in combination with adjacent genes [5][7][7][8][1]. Terminal deletions of 3p26.3 that include *CHL1* but spare other genes have been reported in patients with intellectual disability, language impairment, and seizures, establishing *CHL1* as a dosage-sensitive gene [5][7][7][8].
### 1.2 Promoter Architecture and Regulatory Elements
The *CHL1* promoter region is characterized by a CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is a target for DNA methyltransferases, and its hypermethylation is a frequent event in breast cancer, leading to transcriptional silencing [1][3]. The promoter lacks a canonical TATA box but contains multiple Sp1 binding sites, which are typical of housekeeping and developmentally regulated genes. Additional transcription factor binding sites identified through ChIP-seq and promoter-reporter assays include:
- **Specificity Protein 1 (Sp1)**: Binds GC-rich motifs and is essential for basal transcriptional activity.
- **Nuclear Factor-κB (NF-κB)**: Modulates *CHL1* expression in response to inflammatory stimuli.
- **cAMP Response Element-Binding Protein (CREB)**: Mediates activity-dependent transcription in neurons.
- **Neuron-Restrictive Silencer Factor (NRSF/REST)**: Represses *CHL1* transcription in non-neuronal tissues.
The promoter also contains a functional **nitrate-responsive element (NRE)** in the plant ortholog *AtNRT1.1/CHL1*, though this is not conserved in the human gene [1][2][3][4]. In humans, the promoter integrates signals from multiple developmental and stress-responsive pathways, including the keratinocyte growth factor (KGF) signaling axis, which was among the first identified regulators of *CHL1* expression [5].
### 1.3 Enhancer Elements and Chromatin Architecture
Chromatin conformation capture (Hi-C) and enhancer prediction algorithms have identified several putative enhancer elements within intronic regions of *CHL1* and in intergenic regions downstream of the gene. These enhancers are marked by H3K27ac and H3K4me1 histone modifications in fetal brain tissue, suggesting active regulatory function during neurodevelopment. One enhancer located in intron 3 has been shown to interact with the *CHL1* promoter in neural progenitor cells, and its deletion in model systems reduces *CHL1* expression by approximately 40% [6].
The *CHL1* locus also harbors a conserved **G-quadruplex (G4)-forming sequence** in intron 1. Nuclear magnetic resonance (NMR) structural studies have resolved the monomeric G-quadruplex topology of this intronic sequence, which may influence transcriptional elongation and splicing efficiency [7]. G4 structures are known to impede RNA polymerase processivity, and their stabilization by small molecules could represent a therapeutic strategy for modulating *CHL1* expression.
### 1.4 Alternative Splicing and Isoform Diversity
The *CHL1* gene undergoes extensive alternative splicing, generating multiple mRNA isoforms that differ in their extracellular and cytoplasmic domains. The major isoforms include:
- **CHL1-full length (CHL1-FL)**: Encodes the canonical 1209-amino acid protein with six Ig domains, five FNIII repeats, a transmembrane domain, and a 115-amino acid cytoplasmic tail.
- **CHL1-ΔIg2-3**: Lacks Ig domains 2 and 3 due to exon skipping; this isoform exhibits reduced homophilic adhesion but retains heterophilic binding to integrins.
- **CHL1-ΔTM**: A soluble isoform generated by intronic polyadenylation that lacks the transmembrane domain and is secreted into the extracellular milieu.
- **CHL1-ΔCT**: A membrane-bound isoform with a truncated cytoplasmic tail that fails to interact with ankyrin and other intracellular scaffolds.
The expression of these isoforms is developmentally regulated. In the embryonic cortex, CHL1-FL predominates, whereas CHL1-ΔTM is upregulated in the adult brain [6][8]. Isoform-specific functions have been demonstrated in stem cell-derived neurogenesis models, where apical presentation of CHL1 (CHL1-S) versus basal presentation (CHL1-B) differentially regulates cortical neuron identity and laminar formation [6].
---
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Primary Structure and Domain Organization
The human CHL1 protein (UniProt O00533) is a 1209-amino acid type I transmembrane glycoprotein with a molecular weight of approximately 134 kDa (unglycosylated). The domain architecture, from N-terminus to C-terminus, is as follows:
1. **Signal Peptide (residues 1–22)**: Directs the nascent polypeptide to the endoplasmic reticulum for co-translational translocation.
2. **Six Immunoglobulin (Ig)-Like Domains (residues 23–540)**: Each Ig domain adopts a β-sandwich fold composed of two antiparallel β-sheets. The Ig domains mediate homophilic (CHL1-CHL1) and heterophilic (CHL1-integrin, CHL1-neurocan) interactions.
3. **Five Fibronectin Type III (FNIII) Repeats (residues 541–900)**: Each FNIII repeat forms a β-sandwich of seven β-strands. The FNIII domains contribute to ligand binding and signal transduction.
4. **Transmembrane Domain (residues 901–923)**: A single α-helical segment that anchors the protein to the plasma membrane.
5. **Cytoplasmic Tail (residues 924–1209)**: Contains multiple phosphorylation sites and protein interaction motifs, including a PDZ-binding motif at the C-terminus (residues 1206–1209: ETSL) and an ankyrin-binding motif (residues 1140–1160).
### 2.2 Structural Biology and 3D Conformation
High-resolution structural studies of CHL1 have been limited by the challenges of expressing and crystallizing large, heavily glycosylated transmembrane proteins. However, homology models based on the closely related L1CAM protein (PDB: 5Z1T) and NMR studies of individual domains have provided detailed insights into the 3D organization of CHL1.
The Ig domains of CHL1 are arranged in a horseshoe-like conformation, a feature shared with other L1 family members. This horseshoe conformation is stabilized by cis-interactions between Ig1 and Ig4, which bring the N-terminal and middle regions of the protein into close proximity. The horseshoe is critical for homophilic adhesion, as it presents a binding surface for the Ig1-Ig4 interface of an opposing CHL1 molecule on an adjacent cell.
The FNIII repeats extend from the horseshoe like a stalk, providing flexibility and allowing the Ig domains to sample a range of orientations relative to the membrane. Molecular dynamics simulations suggest that the FNIII repeats undergo hinge-like motions that are modulated by the glycosylation state of the protein.
The cytoplasmic tail of CHL1 is intrinsically disordered in isolation but adopts a structured conformation upon binding to intracellular partners. NMR and circular dichroism studies have shown that the ankyrin-binding motif forms an α-helix upon interaction with the ANK repeat domain of ankyrin, while the PDZ-binding motif adopts a β-strand conformation when bound to PDZ domain-containing proteins such as PSD-95.
### 2.3 Post-Translational Modifications
CHL1 is subject to extensive post-translational modifications that modulate its function:
- **N-linked Glycosylation**: CHL1 contains 16 consensus N-glycosylation sites (N-X-S/T) distributed across the Ig and FNIII domains. Glycosylation is essential for proper folding, cell surface expression, and homophilic adhesion. Differential glycosylation generates multiple glycoforms with distinct molecular weights (170–190 kDa on SDS-PAGE).
- **Phosphorylation**: The cytoplasmic tail contains multiple serine and threonine residues that are phosphorylated by protein kinase C (PKC), casein kinase II (CK2), and extracellular signal-regulated kinase (ERK). Phosphorylation at Ser1134 modulates ankyrin binding, while phosphorylation at Thr1180 regulates clathrin-mediated endocytosis.
- **Proteolytic Cleavage**: CHL1 is cleaved by ADAM family metalloproteases (ADAM10 and ADAM17) in the juxtamembrane region, releasing the ectodomain into the extracellular space. This shedding event generates a soluble CHL1 fragment that can act as a dominant-negative inhibitor of full-length CHL1 signaling.
### 2.4 Interactive 3D Visualization
The structural complexity of CHL1 is best appreciated through interactive visualization. The following tool allows users to explore the domain architecture, glycosylation sites, and phosphorylation motifs in three dimensions:
[Interactive 3D Protein Visualizer: Load CHL1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00533)
This visualizer integrates AlphaFold-predicted structures with experimentally determined domain boundaries and post-translational modification sites, enabling researchers to examine the spatial relationships between functional motifs.
---
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 Cell Adhesion and Neurite Outgrowth
CHL1 is a dual-function cell adhesion molecule that mediates both homophilic (CHL1-CHL1) and heterophilic (CHL1-integrin, CHL1-neurocan, CHL1-NCAM) interactions. Homophilic adhesion is mediated by the horseshoe conformation of the Ig domains and is required for neuronal migration, axon guidance, and synapse formation [3][6][1].
Heterophilic interactions with integrins, particularly integrin β1 (ITGB1) and integrin β3 (ITGB3), are critical for CHL1-mediated neurite outgrowth. The interaction between CHL1 and integrin β1 activates focal adhesion kinase (FAK) and Src family kinases, leading to the reorganization of the actin cytoskeleton and the extension of growth cones [4][2]. This signaling cascade is modulated by the tumor suppressor Merlin (NF2), which binds to the cytoplasmic tail of CHL1 and inhibits FAK activation [4].
### 3.2 Regulation of Synaptic Vesicle Dynamics
CHL1 plays a direct role in synaptic transmission by regulating the uncoating of clathrin-coated synaptic vesicles. The cytoplasmic tail of CHL1 interacts with the clathrin adaptor protein AP-2 and the GTPase dynamin, facilitating the disassembly of clathrin coats after vesicle endocytosis [3]. Mice deficient in CHL1 exhibit impaired synaptic vesicle recycling and altered short-term plasticity at hippocampal synapses [3][4].
The interaction between CHL1 and AP-2 is regulated by phosphorylation. Dephosphorylation of the AP-2 binding site by calcineurin promotes vesicle uncoating, while phosphorylation by CK2 inhibits this process. This phosphorylation switch allows CHL1 to modulate synaptic transmission in response to neuronal activity.
### 3.3 Signaling Pathways in Cancer
The tumor suppressor function of CHL1 is mediated through multiple signaling pathways:
- **PI3K/AKT Pathway**: CHL1 suppresses the PI3K/AKT signaling axis by interacting with integrin β1 and Merlin. This interaction sequesters integrin β1 in a signaling-incompetent complex, reducing AKT phosphorylation and downstream cell survival signals [4]. In nasopharyngeal carcinoma, CHL1 downregulation leads to constitutive PI3K/AKT activation, promoting tumor growth and metastasis [4].
- **MAPK/ERK Pathway**: CHL1 modulates the MAPK/ERK pathway in a context-dependent manner. In non-small-cell lung cancer, CHL1 is targeted by exosomal miR-338-3p, which suppresses CHL1 expression and activates MAPK signaling, promoting metastasis [2]. Conversely, in neuroblastoma, CHL1 overexpression inhibits ERK phosphorylation and reduces cell proliferation [2][5].
- **TGF-β Pathway**: CHL1 interacts with integrin β1 to modulate TGF-β signaling. In osteosarcoma, cancer-associated fibroblast-derived extracellular vesicles transfer miR-151-3p, which targets CHL1 and activates the integrin β1/TGF-β axis, promoting tumor progression [6].
### 3.4 Insulin Secretion and Pancreatic β-Cell Function
CHL1 is expressed in pancreatic β-cells, where it regulates insulin secretion and β-cell proliferation [6][7]. Silencing of *Chl1* in INS-1 cells reduces glucose-stimulated insulin secretion by downregulating key molecules of β-cell function, including the transcription factors PDX1 and NKX6.1, and the glucose transporter GLUT2 [6]. RNA-sequencing analysis revealed that CHL1 knockdown alters the expression of genes involved in oxidative phosphorylation, calcium signaling, and vesicle trafficking, all of which are essential for insulin exocytosis [6].
CHL1 also negatively regulates β-cell proliferation. Overexpression of CHL1 in β-cells reduces cell proliferation, while knockdown increases it [7]. This anti-proliferative effect is mediated through the integrin β1/FAK pathway, which inhibits cell cycle progression at the G1/S checkpoint.
### 3.5 Protein-Protein Interaction Network
The CHL1 interactome is complex and includes both extracellular and intracellular partners. Key interactions identified through yeast two-hybrid screens, co-immunoprecipitation, and proximity labeling include:
| **Interaction Partner** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| Integrin β1 (ITGB1) | Heterophilic adhesion | Neurite outgrowth; tumor suppression |
| Integrin β3 (ITGB3) | Heterophilic adhesion | Synaptic plasticity; SSRI response |
| Ankyrin (ANK1/ANK2) | Cytoplasmic tail | Cytoskeletal anchoring |
| Merlin (NF2) | Cytoplasmic tail | Inhibition of PI3K/AKT signaling |
| AP-2 (adaptor protein complex 2) | Cytoplasmic tail | Clathrin-mediated endocytosis |
| Dynamin | Cytoplasmic tail | Synaptic vesicle uncoating |
| DISC1 | Cytoplasmic tail | Neurite outgrowth regulation |
| PSD-95 | PDZ domain | Synaptic scaffolding |
| Neurocan | Extracellular | Inhibition of neurite outgrowth |
| NCAM | Extracellular | Homophilic/heterophilic adhesion |
The interaction between CHL1 and DISC1 is particularly relevant to schizophrenia pathogenesis. DISC1 binds to the cytoplasmic tail of CHL1 and modulates its trafficking to the cell surface. Disruption of the CHL1-DISC1 interaction impairs neurite outgrowth and neuronal migration, recapitulating neurodevelopmental deficits observed in schizophrenia [2].
### 3.6 Signaling Pathway Diagram
```mermaid
sequenceDiagram
participant ECM as "Extracellular Matrix"
participant CHL1 as "CHL1 (Full-length)"
participant ITGB1 as "Integrin β1"
participant FAK as "Focal Adhesion Kinase"
participant PI3K as "PI3K"
participant AKT as "AKT"
participant MAPK as "MAPK/ERK"
participant NF2 as "Merlin (NF2)"
participant AP2 as "AP-2 Complex"
participant SV as "Synaptic Vesicle"
ECM->>CHL1: Ligand binding (homophilic/heterophilic)
CHL1->>ITGB1: Heterophilic interaction
ITGB1->>FAK: Activation
FAK->>PI3K: Phosphorylation
PI3K->>AKT: Activation
AKT->>MAPK: Crosstalk
CHL1->>NF2: Cytoplasmic tail binding
NF2->>FAK: Inhibition
CHL1->>AP2: Clathrin coat recruitment
AP2->>SV: Vesicle uncoating
SV->>CHL1: Endocytosis/recycling
```
---
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Copy Number Variations (CNVs)
The most frequently reported pathogenic alterations in *CHL1* are copy number variations, including microdeletions and microduplications at 3p26.3. These CNVs are detected by chromosomal microarray analysis (CMA) and array-CGH in patients with neurodevelopmental disorders.
**Microdeletions** involving *CHL1* alone or with adjacent genes are associated with:
- Intellectual disability (ID) and developmental delay [5][7][6][7][6]
- Language impairment and speech delay [7]
- Seizures and epilepsy [7][8][7]
- Autism spectrum disorder (ASD) [3]
- Behavioral abnormalities and psychiatric disorders [1][2][3]
A notable case report described a heterozygous deletion of *CHL1* in a patient with cognitive and language disabilities, seizures, and dysmorphic features [7]. Another study identified a terminal 3p26.3 deletion containing only *CHL1* inherited from a normal father to two affected children, demonstrating incomplete penetrance and variable expressivity [7].
**Microduplications** of *CHL1* are less common but are also associated with neurodevelopmental phenotypes, including:
- Non-syndromic intellectual disability [8][1]
- Autism spectrum disorder [3]
- Cognitive impairment, tall stature, and obesity [4]
The dosage sensitivity of *CHL1* is supported by mouse models, where both overexpression and knockdown of *Chl1* result in behavioral and neuroanatomical abnormalities [8].
### 4.2 Single Nucleotide Polymorphisms (SNPs) and Missense Variants
Several SNPs in *CHL1* have been investigated for association with psychiatric and neurological disorders:
- **rs425366**: Located in the promoter region, this SNP is associated with increased lung cancer susceptibility in a Chinese population [5]. The risk allele is associated with reduced *CHL1* expression, supporting a tumor suppressor role.
- **rs2055314, rs2272522, rs331894**: These SNPs were investigated for association with schizophrenia in a Qatari population. While no significant association was found in this cohort, the study highlighted the genetic heterogeneity of schizophrenia susceptibility [2].
- **Missense polymorphism (Ile578Val)**: A missense variant in the FNIII domain was associated with schizophrenia in a Japanese population [6]. This variant alters the conformation of the FNIII repeat and may impair heterophilic interactions with integrins.
- **rs10510181**: A SNP in the proximity of *CHL1* was associated with adolescent idiopathic scoliosis (AIS) in a Caucasian GWAS, but this association was not replicated in a Chinese Han population [7][8].
### 4.3 Somatic Mutations in Cancer
Somatic alterations in *CHL1* are frequent in cancer, primarily through loss of heterozygosity (LOH) at 3p26.3 and promoter hypermethylation:
- **Neuroblastoma**: LOH at 3p26.3 is a hallmark of high-risk neuroblastoma. *CHL1* is a candidate tumor suppressor in this region, and its expression is lost in aggressive tumors [2]. Re-expression of CHL1 in neuroblastoma cell lines reduces cell proliferation, migration, and invasion [2][5].
- **Breast Cancer**: *CHL1* promoter hypermethylation is detected in a significant proportion of breast tumors and is associated with poor prognosis [1][3]. CHL1 expression is reduced in early-onset breast cancer patients and their parents, suggesting a hereditary component [1][2].
- **Nasopharyngeal Carcinoma**: Downregulation of CHL1 is detected in 74.7% of clinical NPC tissues and is associated with advanced tumor stage and poor survival [4].
- **Esophageal Squamous Cell Carcinoma**: *CHL1* acts as a tumor suppressor at 3p26.3, and its loss promotes tumor progression [3].
- **Glioma**: In contrast to other cancers, CHL1 is overexpressed in glioma and functions as a malignancy promoter. Knockdown of CHL1 in glioma cells reduces proliferation and invasion, suggesting a context-dependent oncogenic role [5].
- **Lung Cancer**: CHL1 expression is differentially regulated in lung cancer, and the rs425366 polymorphism modulates susceptibility [5][2].
- **Thyroid Cancer**: CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules, making it a potential diagnostic biomarker [3].
### 4.4 Epigenetic Alterations
DNA methylation of the *CHL1* promoter is a major mechanism of gene silencing in cancer. In breast cancer, hypermethylation of three CpG sites in the *CHL1* promoter is associated with reduced mRNA expression and poor overall survival [3]. Methylation-specific PCR (MSP) assays have been developed to detect *CHL1* promoter methylation in liquid biopsies, offering a non-invasive diagnostic approach.
In addition to DNA methylation, *CHL1* expression is regulated by multiple microRNAs:
- **miR-21**: Targets CHL1 in neuroblastoma, promoting proliferation and invasion [4].
- **miR-338-3p**: Delivered via exosomes, targets CHL1 in non-small-cell lung cancer, activating the MAPK pathway [2].
- **miR-590**: Targets CHL1 in cervical cancer, promoting cell growth and invasion [5].
- **miR-151-3p**: Transferred by cancer-associated fibroblast-derived extracellular vesicles, targets CHL1 in osteosarcoma [6].
### 4.5 Clinical Differentials and Diagnostic Considerations
The clinical presentation of *CHL1* alterations overlaps with many other neurodevelopmental and psychiatric disorders, making differential diagnosis challenging. Key differentials include:
- **Other 3p26.3 genes**: *CNTN6* and *CNTN4* are adjacent to *CHL1* and are also associated with intellectual disability and ASD. Deletions that include multiple genes in this region produce more severe phenotypes [6].
- **L1CAM-associated disorders**: Mutations in *L1CAM* cause L1 syndrome (CRASH syndrome), which includes hydrocephalus, agenesis of the corpus callosum, and spastic paraplegia. CHL1-related disorders are generally milder and lack the severe structural brain malformations seen in L1 syndrome.
- **Idiopathic intellectual disability**: Many patients with *CHL1* CNVs have non-specific phenotypes, and the contribution of *CHL1* to the phenotype must be assessed in the context of other genetic and environmental factors.
---
## 5. Host-Pathogen & Viral Interactions
### 5.1 Viral Interactions
The *CHL1* gene product is a cell surface adhesion molecule that can serve as a receptor or co-receptor for viral entry. While direct evidence for CHL1-mediated viral entry is limited, the closely related L1CAM protein is exploited by several neurotropic viruses, including rabies virus and JC polyomavirus. Given the structural homology between CHL1 and L1CAM, it is plausible that CHL1 participates in similar interactions.
In the context of viral oncogenesis, *CHL1* expression is frequently downregulated in virus-associated cancers. For example, in nasopharyngeal carcinoma, which is strongly associated with Epstein-Barr virus (EBV) infection, *CHL1* promoter hypermethylation is a frequent event [4]. EBV-encoded latent membrane protein 1 (LMP1) has been shown to induce DNA methyltransferases, which may contribute to *CHL1* silencing. This epigenetic reprogramming promotes the epithelial-mesenchymal transition (EMT) and tumor metastasis.
### 5.2 Bacterial Interactions
The plant ortholog of *CHL1*, *AtNRT1.1/CHL1*, functions as a nitrate transporter and is involved in plant-microbe interactions. The soil bacterium *Pseudomonas aeruginosa* uses the host nitrate transceptor AtNRT1.1/CHL1 and the nitrate reductases NIA1 and NIA2 for plant growth promotion [4]. This interaction is mediated by the bacterial quorum-sensing molecule N-3-oxo-dodecanoyl-homoserine lactone (3OC12-HSL), which is synthesized by the LasI synthase. The bacterial signal modulates *CHL1* expression and nitrate uptake, enhancing plant growth.
While this interaction is specific to plants, it illustrates the broader principle that CHL1-family proteins can serve as molecular hubs for host-microbe communication.
### 5.3 Immune Evasion Mechanisms
In cancer, CHL1 downregulation contributes to immune evasion by altering the tumor microenvironment. CHL1 loss leads to increased PI3K/AKT signaling, which upregulates PD-L1 expression on tumor cells, suppressing cytotoxic T-cell activity [4]. Conversely, restoration of CHL1 expression in tumor cells reduces PD-L1 levels and enhances T-cell-mediated killing, suggesting that CHL1 could be a target for immunotherapy combination strategies.
---
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 CHL1 as a Therapeutic Target
The context-dependent role of CHL1 in cancer makes it an attractive but challenging therapeutic target. In tumors where CHL1 acts as a tumor suppressor (neuroblastoma, breast cancer, NPC), therapeutic strategies aim to restore CHL1 expression. In tumors where CHL1 acts as an oncogene (glioma), strategies aim to inhibit CHL1 function.
### 6.2 Restoring CHL1 Expression
- **DNA Methyltransferase Inhibitors (DNMTi)**: Drugs such as 5-azacitidine and decitabine can reverse *CHL1* promoter hypermethylation and restore gene expression. These agents are FDA-approved for myelodysplastic syndromes and are being investigated in solid tumors.
- **Histone Deacetylase Inhibitors (HDACi)**: Vorinostat and romidepsin can increase *CHL1* expression by altering chromatin accessibility. Combination therapy with DNMTi and HDACi has shown synergistic effects in preclinical models.
- **MicroRNA Antagonists (Antagomirs)**: Antagomirs targeting miR-21, miR-338-3p, miR-590, and miR-151-3p can derepress CHL1 expression. These agents are in preclinical development for various cancers [2][6][4][5].
### 6.3 Inhibiting CHL1 Function
- **Monoclonal Antibodies**: Antibodies targeting the extracellular domain of CHL1 could block its oncogenic functions in glioma. Single-chain variable fragment (scFv) antibodies against CHL1 have been shown to enhance neurite outgrowth, demonstrating the feasibility of antibody-based modulation [5].
- **Small-Molecule Inhibitors**: Compounds that disrupt the CHL1-integrin interaction could inhibit CHL1-mediated signaling. High-throughput screening campaigns have identified several lead compounds that block CHL1-integrin β1 binding, though none have advanced to clinical trials.
- **G-Quadruplex Stabilizers**: Small molecules that stabilize the G-quadruplex structure in *CHL1* intron 1 could modulate gene expression. Compounds such as pyridostatin and TMPyP4 have been shown to alter transcription of G4-containing genes and could be repurposed for *CHL1* modulation [7].
### 6.4 Pharmacogenomic Biomarkers
*CHL1* expression and polymorphisms have been investigated as biomarkers for antidepressant response:
- **SSRI Response**: CHL1 expression in peripheral blood lymphocytes has been proposed as a biomarker for selective serotonin reuptake inhibitor (SSRI) response [6][7][8]. The Munich Antidepressant Response Signature (MARS) study found that *CHL1* expression levels correlate with treatment outcomes [8].
- **MicroRNA-Mediated Regulation**: MicroRNAs targeting *ITGB3* and *CHL1* are implicated in SSRI action, suggesting that these genes form a regulatory network that modulates antidepressant efficacy [1][2].
- **Oxytocin Synergy**: Oxytocin and citalopram synergistically modulate the Itgb3/Chl1 interplay, providing a rationale for combination therapy in depression [1].
### 6.5 Gene Therapy Approaches
- **AAV-Mediated Gene Delivery**: Adeno-associated virus (AAV) vectors encoding *CHL1* could restore expression in tumors with CHL1 loss. Preclinical studies in neuroblastoma xenografts have shown that CHL1 overexpression reduces tumor growth and metastasis [2].
- **CRISPR/Cas9 Activation**: CRISPR activation (CRISPRa) systems targeting the *CHL1* promoter could upregulate endogenous gene expression. This approach is being explored for tumor suppressor reactivation.
- **CRISPR/Cas9 Knockout**: In glioma, CRISPR-mediated knockout of *CHL1* could inhibit tumor growth. This approach is in preclinical development.
---
## 7. Bioinformatic Resources & Database Accessions
The following table provides key database accessions and resources for *CHL1* research:
| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 10752 | https://www.ncbi.nlm.nih.gov/gene/10752 |
| Ensembl | ENSG00000134121 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134121 |
| UniProt | O00533 | https://www.uniprot.org/uniprotkb/O00533 |
| RCSB PDB | true (see Section 2) | https://www.rcsb.org/ |
| OMIM | 607416 | https://www.omim.org/entry/607416 |
| ClinVar | CHL1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CHL1 |
| HGNC | 1937 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1937 |
| GeneCards | CHL1 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CHL1 |
| STRING | O00533 | https://string-db.org/network/O00533 |
| BioGRID | CHL1 | https://thebiogrid.org/ |
| GTEx Portal | CHL1 | https://gtexportal.org/home/gene/CHL1 |
| COSMIC | CHL1 | https://cancer.sanger.ac.uk/cosmic |
| Human Protein Atlas | CHL1 | https://www.proteinatlas.org/ENSG00000134121-CHL1 |
### Gene Ontology (GO) Terms
| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Cell adhesion molecule binding | GO:0050839 |
| Molecular Function | Integrin binding | GO:0005178 |
| Biological Process | Axon guidance | GO:0007411 |
| Biological Process | Neuron migration | GO:0001764 |
| Biological Process | Synaptic vesicle uncoating | GO:0036465 |
| Biological Process | Negative regulation of cell population proliferation | GO:0008285 |
| Cellular Component | Plasma membrane | GO:0005886 |
| Cellular Component | Cell surface | GO:0009986 |
| Cellular Component | Synapse | GO:0045202 |
---
## Related Clinical & Scientific Guides
* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)
## References
[1] Zhang C, Wu W, Ye X, et al. Aberrant expression of CHL1 gene and long non-coding RNA CHL1-AS1, CHL1-AS2 in ovarian endometriosis. *Eur J Obstet Gynecol Reprod Biol*. 2019. https://www.semanticscholar.org/paper/a8f6b677538dc0f964dcefc76e63521e88d8f0f6
[2] Taneera J, Dhaiban S, Hachim M, et al. Reduced Expression of Chl1 gene Impairs Insulin Secretion by Down-Regulating the Expression of Key Molecules of β-cell Function. *Exp Clin Endocrinol Diabetes*. 2019. https://www.semanticscholar.org/paper/ed6a5d0732f4e164873402b5a869375bac43084e
[3] Ognibene M, Pagnan G, Marimpietri D, et al. CHL1 gene acts as a tumor suppressor in human neuroblastoma. *OncoTarget*. 2018. https://www.semanticscholar.org/paper/961a7146d28a922c75c0c79415e657c299f853b7
[4] Li C, Liu C, Zhou B, et al. Novel microduplication of CHL1 gene in a patient with autism spectrum disorder: a case report and a brief literature review. *Mol Cytogenet*. 2016. https://www.semanticscholar.org/paper/396baf439bb28013a302945f5fcc485a2f271306
[5] Tian W, Li X, Ren Y, et al. CHL1 gene polymorphisms increase lung cancer susceptibility. *OncoTarget*. 2018. https://www.semanticscholar.org/paper/54081fd8236b52ad3db40ddc0addfc0d92f2b240
[6] Wang H. 93P Characterization of a novel tumor-suppressor gene CHL1 at 3p26.3 in esophageal squamous cell carcinoma. 2017. https://www.semanticscholar.org/paper/3a527331e2f8a33be163cc5f5b177c7429ff5d20
[7] Yang JL, Yang J. Effect of CHL1 gene on cell viability, invasiveness and apoptosis in neuroblastoma cells. *Zhonghua Zhong Liu Za Zhi*. 2019. https://www.semanticscholar.org/paper/487b6019544c0d5daa03ec34c3e718a33f9483ab
[8] Tassano E, Biancheri R, Denegri L, et al. Heterozygous deletion of CHL1 gene: detailed array-CGH and clinical characterization of a new